Use of trans-palmitoleate in identifying and treating metabolic disease

Patent metadata

Field	Value
Publication number	US-2016361284-A1
Application number	US-201615248310-A
Country	US
Kind code	A1
Filing date	Aug 26, 2016
Priority date	Jul 9, 2010
Publication date	Dec 15, 2016
Grant date	—

Abstract

The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.

First claim

We claim:

1 . A method of reducing metabolic risk factor by decreasing triglyceride levels and/or raising HDL-C levels in a subject comprising administering to the subject a pharmaceutical, nutraceutical or dietary formulation, or dietary supplement, comprising trans-palmitoleate, wherein trans-palmitoleate is at least 6% of total fatty acids present in the formulation or supplement.

2 . The method of claim 1 , wherein the formulation or supplement is substantially free of milk.

Assignees

• Harvard College

Inventors

• Mozaffarian Dariush
• Cao Haiming
• Hotamisligil Gokhan S

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A23L33/12

  Fatty acids or derivatives thereof · CPC title

• A61K31/201 Primary

  having one or two double bonds, e.g. oleic, linoleic acids · CPC title

• C07C57/03

  Monocarboxylic acids · CPC title